Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucitanib in Advanced Recurrent or Metastatic Thymic Carcinoma
NCT07824505Phase 2Completed
- Sponsor
- Haihe
- Start
- Aug 2018
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lucitanib in thymic carcinoma (TC) and solid tumor (3 arms), sponsored by Haihe. Primary endpoints: Safety and Tolerability and Progression-Free Survival. Started Aug 2018; status: completed.
02
Drugs
lucitanib
03
Conditions
thymic carcinoma (TC)solid tumor
Beyond the preview
Go deeper on NCT07824505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07824505.